KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib
Xiaoqi Wang
◽
Guangyuan Li
◽
Jaime Merchan
◽
Balazs Halmos
2020 ◽
Vol 17
◽
pp. 448-459
Yuwen He
◽
Danyang Chen
◽
Yanmei Yi
◽
Shanshan Zeng
◽
Shuang Liu
◽
...
2008 ◽
Vol 7
(7)
◽
pp. 1923-1930
◽
Akihiko Miyanaga
◽
Akihiko Gemma
◽
Rintaro Noro
◽
Kiyoko Kataoka
◽
Kuniko Matsuda
◽
...
2011 ◽
Vol 6
(8)
◽
pp. 1313-1319
◽
Sung-Keum Seo
◽
Hyeon-Ok Jin
◽
Sang-Hyeok Woo
◽
Young-Sun Kim
◽
Sungkwan An
◽
...
2012 ◽
Vol 7
(10)
◽
pp. 1161-1172
◽
Samiha Mateen
◽
Komal Raina
◽
Anil K. Jain
◽
Chapla Agarwal
◽
Daniel Chan
◽
...
2015 ◽
Vol 10
(2)
◽
pp. 126-130
Yong Tian
◽
Cong Chen
◽
Yu Zhang
◽
Zhen Zhang
◽
Haiyan Xie
Bingtao Liu
◽
Hongbin Li
◽
Xiongxiong Liu
◽
Feifei Li
◽
Weiqiang Chen
◽
...
2021 ◽
Vol 561
◽
pp. 120-127
Joo-Young Kang
◽
Jin Woo Park
◽
Yusang Hwang
◽
Ja Young Hahm
◽
Junyoung Park
◽
...
Q. Li
◽
S. Li
◽
L. Niu
◽
S. Yang
◽
H. Niu
◽
...
Close
Export Citation Format
Close
Share Document
Close